Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

The following tables contain certain financial information by geographic area:


	December 31, 2024
(In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenue from external customers	$	3,237.3	$	2,171.5	$	955.6	$	366.9	$	482.2	$	7,213.5
Revenue from anti-CD20 therapeutic programs	1,673.6		0.6		—		—		75.7		1,749.9
Contract manufacturing, royalty and other revenue	395.0		0.4		—		257.2		—		652.6
Long-lived assets	1,366.1		2,139.2		13.3		8.5		10.6		3,537.7

	December 31, 2023
(In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenue from external customers	$	3,141.4	$	2,127.4	$	868.0	$	649.4	$	460.5	$	7,246.7
Revenue from anti-CD20 therapeutic programs	1,618.5		0.4		—		—		70.7		1,689.6
Contract manufacturing, royalty and other revenue	673.6		11.7		—		214.0		—		899.3
Long-lived assets	1,443.0		2,248.0		17.5		8.3		12.9		3,729.7

	December 31, 2022
(In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenue from external customers	$	3,469.3	$	2,401.3	$	926.2	$	672.1	$	518.9	$	7,987.8
Revenue from anti-CD20 therapeutic programs	1,636.4		0.1		—		—		64.0		1,700.5
Contract manufacturing, royalty and other revenue	425.8		11.7		—		47.6		—		485.1
Long-lived assets	1,369.4		2,275.8		21.0		13.7		22.6		3,702.5

(1) Represents amounts related to Europe less those attributable to Germany.

Reconciliation of revenue from segments to consolidated

The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Total revenue	$	9,675.9	$	9,835.6	$	10,173.4
Less cost and expense:
Cost of sales, excluding amortization and impairment of acquired intangible assets:
Product cost of sales	1,604.2		1,787.2		1,504.8
Royalty cost of sales	706.2		746.2		773.5
Research and development:
Milestone and upfront expense	61.5		16.6		76.2
Research and discovery	201.5		212.5		289.4
Early stage programs	286.6		361.0		289.9
Late stage programs	209.7		250.5		484.5
Marketed products	534.7		766.1		361.5
Other research and development costs(1)	747.8		855.3		729.6
Selling, general and administrative	2,403.7		2,549.7		2,403.6
Other segment expense(2)	1,287.8		1,129.4		213.5
Net Income attributable to Biogen Inc.	$	1,632.2	$	1,161.1	$	3,046.9

(1) Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.

(2) Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; gain on sale of priority review voucher, net; gain on sale of building, net; other (income) expense, net; income tax (benefit) expense; equity in (income) loss of investee, net of tax; and net income (loss) attributable to noncontrolling interests, net of tax.